Festival of Biologics 2025 x KACTUS

By Hannah Flaherty

August 14, 2025

Menu

What is the Festival of Biologics?

The Festival of Biologics unites leading minds from pharma, biotech, academia, and investment to exchange breakthroughs, tackle industry challenges, and chart the next chapter in large molecule therapeutics. Covering antibodies, immunotherapy, cell & gene therapy, biosimilars, manufacturing, and more, it’s a three-day deep dive into the science and business of biologics.

Event Overview

Venue: Exhibition Center Basel, Messepl. 10, 4005 Basel, Switzerland

Dates: September 30th to October 2nd

Conference Day 1: Tuesday 30 September 2025 09:00 - 17:00
Conference Day 2: Wednesday 1 October 2025 09:00 - 17:00
Conference Day 3: Thursday 2 October 2025 09:00 - 17:00

Booth #259

Event Schedule

The Festival of Biologics in Basel will span three days, featuring a diverse lineup of speakers and topics each day. For a detailed overview of the daily schedule, including specific times and further information on each talk, please refer to the Festival of Biologics agenda.

Day 1 — 30 September 2025

Registration Opens: 08:00
Exhibit Hall: 08:00–17:00
Presentations: 09:00–17:00
Topics include:

Protein Engineering
Antibodies for Immunotherapy
Cell Therapy
AI & Machine Learning for Discovery
And more

Networking Drinks: 17:00

Day 2 — 1 October 2025

Registration Opens: 08:00
Exhibit Hall: 08:00–17:00
Presentations: 09:00–17:00
Topics include:

Translational Research
Cell Therapy
AI & Machine Learning in Clinical Trials
Therapeutic Vaccine Development
And more

Roundtables: 11:40–12:45

Antibodies
Immunotherapy
Commercialization & Biosimilars
Clinical Trials
Bioprocessing

Networking Drinks: 17:00

Day 3 — 2 October 2025

Registration Opens: 08:00
Exhibit Hall: 08:00–17:00
Presentations: 09:00–17:00
Topics include:

Antibodies for Immunotherapy
Cell & Gene Therapy
Biosimilar Manufacturing
Late-Stage Development
And more

Keynotes: 13:00–15:15
Conference Close: 17:00

Insightful Presentation Alert

Don’t miss Anil Kumar, as he presents:

Title: Advances in HLA/MHC Molecular Design and Engineering for Immunological Research
Date: September 30, 2025 at 3:00pm

Abstract:
Major Histocompatibility Complex (MHC) molecules, referred to as Human Leukocyte Antigens (HLA) in humans, constitute a highly polymorphic family of cell surface glycoproteins. These molecules present intracellularly processed peptide antigens by forming stable MHC–peptide complexes. Following assembly, the complexes are trafficked to the cell membrane, where they are recognized by antigen-specific T cell receptors (TCRs), thereby triggering downstream adaptive immune responses.

Given the central role of MHC molecules in antigen presentation and TCR recognition, they have become indispensable tools for TCR-based therapeutic research. To support this growing demand, KACTUS has developed a comprehensive portfolio of high-quality recombinant MHC products, including MHC monomers, tetramers, peptide-ready MHCs, as well as custom production services for both MHCs and TCRs. Our offerings span a broad range of MHC alleles and clinically relevant targets such as NY-ESO-1, KRAS, and AFP, providing versatile solutions to advance drug discovery and immunotherapy development.

About KACTUS

KACTUS excels in crafting and producing an array of superior-grade, highly active recombinant proteins and enzymes, catering to diverse sectors like antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. Our expansive catalog, boasting over 2500 recombinant proteins, encompasses a wide spectrum of targets, species, tags, and labels, each thoughtfully chosen to address the specific, unmet needs of scientists engaged in drug development. The hallmark of our product selection process is a rigorous emphasis on exceptional quality and a steadfast commitment to ensuring reliable supply, thereby upholding the highest standards of excellence and client satisfaction.